AYTU BioPharma, Inc. (AYTU) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Sep 22, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AYTU SEC filings page.
AYTU BioPharma, Inc. (AYTU) reported $57.6M in revenue for fiscal year 2026, down 13.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is converting a shrinking revenue base into cash, yet gross-margin erosion keeps net losses in place.
FY2026 produced operating cash flow and free cash flow of roughly$3.3M each while the company still reported a net loss of$14.3M . Because inventory and receivables both declined, the cash improvement looks more like working-capital release than a demonstrated turnaround in underlying earnings.
Gross margin fell from
FY2026's current ratio of 1.1x and debt-to-equity ratio of 0.3x indicate modest near-term coverage without a debt-heavy structure. Liabilities stood at
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AYTU BioPharma, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
AYTU BioPharma, Inc. held $26.3M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations generated $3.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and AYTU BioPharma, Inc. scores 86/100 among other emerging companies.
AYTU BioPharma, Inc. had 11M shares outstanding at the end of fiscal year 2026, against 10M in fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and AYTU BioPharma, Inc. scores 25/100 among other emerging companies.
AYTU BioPharma, Inc. reported no research and development spending in fiscal year 2026. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and AYTU BioPharma, Inc. scores 1/100 among other emerging companies.
AYTU BioPharma, Inc. reported revenue of $57.6M in fiscal year 2026, against $66.4M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and AYTU BioPharma, Inc. scores 36/100 among other emerging companies.
AYTU BioPharma, Inc.'s operations generated $3.3M of cash in fiscal year 2026, against $1.9M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and AYTU BioPharma, Inc. scores 98/100 among other emerging companies.
AYTU BioPharma, Inc.'s cash, cash equivalents and investments came to $26.3M at the end of fiscal year 2026, against $69.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and AYTU BioPharma, Inc. scores 37/100 among other emerging companies.
AYTU BioPharma, Inc. scores -4.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($22.0M) relative to total liabilities ($69.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AYTU BioPharma, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
AYTU BioPharma, Inc. reported a net loss of $14.3M while generating $3.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
AYTU BioPharma, Inc. reported an operating loss of $8.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
AYTU BioPharma, Inc. generated $16.1M in revenue in Q4 2026. This represents an increase of 6.4% from the same quarter a year earlier. Against the prior quarter it is up 29.8%.
AYTU BioPharma, Inc.'s EBITDA was $863K in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 115.4% from the same quarter a year earlier. Against the prior quarter it is up 126.9%.
AYTU BioPharma, Inc. reported -$15K in net income in Q4 2026. This represents an increase of 99.9% from the same quarter a year earlier. Against the prior quarter it is up 99.7%.
Not reported for Q4 2026.
Cash & Balance Sheet
AYTU BioPharma, Inc. generated $4.4M in free cash flow in Q4 2026, representing cash available after capex. This represents an increase of 57.7% from the same quarter a year earlier. Against the prior quarter it is up 205.1%.
AYTU BioPharma, Inc. held $26.3M in cash against $9.1M in long-term debt as of Q4 2026.
Not reported for Q4 2026.
Margins & Returns
AYTU BioPharma, Inc.'s gross margin was 64.6% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.4 percentage points.
AYTU BioPharma, Inc.'s operating margin was -4.8% in Q4 2026, reflecting core business profitability. This is up 45.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 27.9 percentage points.
AYTU BioPharma, Inc.'s net profit margin was -0.1% in Q4 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 45.2 percentage points. No change is given against Q4 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
AYTU BioPharma, Inc.'s ROE was 0.0% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is up 104.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.9 percentage points.
Capital Allocation
AYTU BioPharma, Inc. reported no research and development spending in Q4 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
AYTU BioPharma, Inc. invested $12K in capex in Q4 2026, funding long-term assets and infrastructure. This represents a decrease of 29.4% from the same quarter a year earlier.
Not reported for Q4 2026.
AYTU Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M+6.4% | $12.4M-32.7% | $15.2M-6.5% | $13.9M-16.2% | $15.1M+3.7% | $18.5M+31.6% | $16.2M-13.5% | $16.6M-7.0% |
| Cost of Revenue | $5.7M+16.7% | $4.8M-14.8% | $5.5M+2.0% | $4.7M+2.5% | $4.9M+37.8% | $5.6M+54.1% | $5.4M+31.1% | $4.6M-4.0% |
| Gross Profit | $10.4M+1.5% | $7.6M-40.7% | $9.6M-10.8% | $9.2M-23.4% | $10.3M-7.2% | $12.8M+23.6% | $10.8M-26.1% | $12.0M-8.1% |
| R&D Expenses | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $216K-79.3% | $162K-73.5% | $522K+0.2% | $426K-28.4% |
| SG&A Expenses | $4.3M+16.5% | $5.0M+21.0% | $5.1M+14.0% | $4.9M-3.9% | $3.7M-8.2% | $4.1M-14.9% | $4.4M-7.3% | $5.1M-18.6% |
| Operating Income | -$777K+89.8% | -$4.1M-267.9% | -$2.0M-16.2% | -$1.5M-61.7% | -$7.6M-235.4% | $2.4M+251.6% | -$1.7M-153.9% | -$930K-7.3% |
| EBITDA | $863K+115.4% | -$3.2M-193.1% | -$1.3M-99.4% | -$701K-273.5% | -$5.6M-15713.9% | $3.4M+1351.9% | -$674K-113.4% | $404K-70.4% |
| Interest Expense | $383K-47.5% | $436K-51.6% | $560K-48.1% | $516K-48.1% | $730K-41.7% | $900K-28.4% | $1.1M-14.8% | $994K-22.5% |
| Income Tax | $11K-97.5% | $10K+108.2% | $0+100.0% | $0-100.0% | $437K-48.0% | -$122K-123.4% | -$283K-136.3% | $405K |
| Net Income | -$15K+99.9% | -$5.6M-240.7% | -$10.6M-1443.1% | $2.0M+33.3% | -$19.8M-329.2% | $4.0M+238.3% | $788K+458.2% | $1.5M+118.2% |
| EPS (Basic) | $0.26+108.2% | -$0.53-181.5% | -$1.05-907.7% | $0.21-12.5% | -$3.18-287.8% | $0.65+225.0% | $0.13+425.0% | $0.24+116.2% |
| EPS (Diluted) | N/A | -$0.53 | -$1.05-303.8% | -$0.08+46.7% | N/A | $0.21 | -$0.26-550.0% | -$0.15+89.9% |
| Diluted Shares (Avg) | N/A | 11M | 10M+18.3% | 19M+114.0% | N/A | 8M | 8M+53.8% | 9M+66.0% |
AYTU Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $105.0M-15.4% | $111.7M-10.1% | $122.0M+5.0% | $125.0M+7.9% | $124.2M+5.2% | $124.2M-3.6% | $116.2M-11.4% | $115.8M-12.8% |
| Current Assets | $61.8M-22.0% | $67.3M-7.2% | $76.2M | $81.1M | $79.2M+27.9% | $72.5M+1.9% | N/A | N/A |
| Cash & Equivalents | $26.3M-15.0% | $26.7M+47.0% | $30.0M+47.2% | $32.6M+62.3% | $31.0M+54.7% | $18.2M-8.0% | $20.4M+4.4% | $20.1M+0.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $6.9M-40.0% | $7.5M-32.5% | $8.7M-21.9% | $10.1M-14.0% | $11.4M-5.8% | $11.1M-16.2% | $11.1M-14.7% | $11.7M-9.5% |
| Accounts Receivable | $22.8M-26.9% | $24.5M-31.6% | $30.9M+21.7% | $33.2M+43.5% | $31.2M+32.4% | $35.8M+19.7% | $25.4M-13.6% | $23.2M-22.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $69.7M-33.7% | $76.5M-14.3% | $107.8M+26.1% | $101.8M+18.4% | $105.2M+16.4% | $89.3M-9.0% | $85.5M-13.1% | $86.0M-14.6% |
| Current Liabilities | $54.7M-13.3% | $60.0M-15.2% | $65.6M+2.4% | $66.0M+7.7% | $63.1M+1.3% | $70.7M-15.5% | $64.0M-0.2% | $61.3M-6.4% |
| Non-Current Liabilities | $15.1M-64.2% | $16.6M-10.9% | $42.2M+97.2% | $35.8M+44.7% | $42.1M+49.7% | $18.6M+29.2% | $21.4M-37.4% | $24.8M-29.8% |
| Long-Term Debt | $9.1M-16.5% | $9.5M+0.1% | $10.0M+0.2% | $10.4M+0.2% | $10.9M+0.2% | $9.5M | $10.0M-33.3% | $10.4M-29.7% |
| Total Equity | $35.3M+86.0% | $35.1M+0.7% | $14.2M-53.8% | $23.2M-22.3% | $19.0M-31.6% | $34.9M+13.4% | $30.8M-6.4% | $29.8M-7.3% |
| Retained Earnings | -$347.8M-4.3% | -$347.8M-10.9% | -$342.2M-7.7% | -$331.6M-4.1% | -$333.5M-4.2% | -$313.7M+0.5% | -$317.7M-1.7% | -$318.5M-2.0% |
Not reported in any period shown, so not listed: Goodwill.
AYTU Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.4M+57.2% | -$4.2M+35.2% | $3.7M+26.5% | -$618K+48.1% | $2.8M+455.7% | -$6.5M-2441.3% | $2.9M+2251.9% | -$1.2M-464.0% |
| Depreciation & Amortization | $1.1M-23.4% | $861K-15.6% | $626K-38.7% | $803K-39.8% | $1.5M-36.6% | $1.0M-44.4% | $1.0M-46.2% | $1.3M-40.2% |
| Stock-Based Compensation | N/A | $148K+6.5% | $283K+87.4% | $114K-34.1% | N/A | $139K-82.9% | $151K-81.6% | $173K-81.4% |
| Capital Expenditures | $12K-29.4% | $0-100.0% | $17K+183.3% | $0-100.0% | $17K-94.8% | $69K | $6K | $136K |
| Free Cash Flow | $4.4M+57.7% | -$4.2M+35.9% | $3.7M+26.2% | -$618K+53.4% | $2.8M+349.4% | -$6.5M-2468.5% | $2.9M | -$1.3M |
| Investing Cash Flow | -$12K+99.6% | $0+100.0% | -$17K-111.7% | $0-100.0% | -$3.0M-8773.5% | -$69K-53.3% | $145K+183.3% | $381K+601.3% |
| Financing Cash Flow | -$4.8M-137.0% | $872K-79.7% | -$6.3M-126.9% | $2.3M+152.0% | $13.0M+1116.6% | $4.3M+711.1% | -$2.8M-2090.5% | $911K+133.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AYTU Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.6%-3.1pp | 61.2%-8.2pp | 63.5%-3.0pp | 66.1%-6.2pp | 67.8%-8.0pp | 69.4%-4.5pp | 66.5%-11.4pp | 72.3%-0.9pp |
| Operating Margin | -4.8%+45.6pp | -32.8%-45.9pp | -13.0%-2.5pp | -10.8%-5.2pp | -50.4%-34.8pp | 13.1%+24.5pp | -10.4%-27.2pp | -5.6%-0.7pp |
| Net Margin | -0.1% | -45.3%-66.9pp | -69.8%-74.6pp | 14.1%+5.3pp | -130.9% | 21.6%+42.2pp | 4.9%+6.0pp | 8.9%+54.5pp |
| Return on Equity | 0.0%+104.4pp | -16.0%-27.4pp | -74.5%-77.1pp | 8.5%+3.5pp | -104.5%-87.8pp | 11.4%+20.8pp | 2.6%+3.2pp | 4.9%+30.2pp |
| Return on Assets | 0.0%+16.0pp | -5.0%-8.2pp | -8.7%-9.4pp | 1.6%+0.3pp | -16.0%-12.0pp | 3.2%+5.5pp | 0.7%+0.8pp | 1.3%+7.4pp |
| Current Ratio | 1.13-0.1x | 1.12+0.1x | 1.16 | 1.23 | 1.26+0.3x | 1.03+0.2x | N/A | N/A |
| Debt-to-Equity | 0.26-0.3x | 0.270.0x | 0.70+0.4x | 0.45+0.1x | 0.57+0.2x | 0.27-2.9x | 0.32-0.1x | 0.35-0.1x |
| Asset Turnover | 0.150.0x | 0.110.0x | 0.120.0x | 0.110.0x | 0.120.0x | 0.150.0x | 0.140.0x | 0.140.0x |
| FCF Margin | 27.3%+8.9pp | -33.7%+1.7pp | 24.1%+6.3pp | -4.5%+3.6pp | 18.4%+26.1pp | -35.4%-33.6pp | 17.9% | -8.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AYTU BioPharma, Inc. AYTU | FY2026 | $57.6M | -$14.3M | -24.8% | $22.0M | 47/100 |
| Talphera, Inc. TLPH | FY2025 | $28K | -$14.3M | N/A | $56.1M | — |
| Gelteq Limited GELS | FY2025 | N/A | -$6.6M | N/A | $5.9M | — |
| Flora Growth Corp. FLGC | FY2025 | $35.7M | -$119.7M | N/A | $21.6M | 32/100 |
| TherapeuticsMD, Inc. TXMD | FY2025 | $3.0M | -$569K | -18.8% | $23.3M | 63/100 |
| Incannex Healthcare Limited IXHL | FY2026 | $0 | -$19.3M | N/A | $40.1M | — |
Where AYTU BioPharma, Inc. Ranks
Frequently Asked Questions
What is AYTU BioPharma, Inc.'s annual revenue?
AYTU BioPharma, Inc. (AYTU) reported $57.6M in total revenue for fiscal year 2026. This represents a -13.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AYTU BioPharma, Inc.'s revenue growing?
AYTU BioPharma, Inc. (AYTU) revenue declined by 13.3% year-over-year, from $66.4M to $57.6M in fiscal year 2026.
Is AYTU BioPharma, Inc. profitable?
No, AYTU BioPharma, Inc. (AYTU) reported a net income of -$14.3M in fiscal year 2026, with a net profit margin of -24.8%.
What is AYTU BioPharma, Inc.'s EBITDA?
AYTU BioPharma, Inc. (AYTU) had EBITDA of -$4.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does AYTU BioPharma, Inc. have?
As of fiscal year 2026, AYTU BioPharma, Inc. (AYTU) had $26.3M in cash and equivalents against $9.1M in long-term debt.
What is AYTU BioPharma, Inc.'s gross margin?
AYTU BioPharma, Inc. (AYTU) had a gross margin of 63.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is AYTU BioPharma, Inc.'s operating margin?
AYTU BioPharma, Inc. (AYTU) had an operating margin of -14.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is AYTU BioPharma, Inc.'s net profit margin?
AYTU BioPharma, Inc. (AYTU) had a net profit margin of -24.8% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is AYTU BioPharma, Inc.'s return on equity (ROE)?
AYTU BioPharma, Inc. (AYTU) has a return on equity of -40.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is AYTU BioPharma, Inc.'s free cash flow?
AYTU BioPharma, Inc. (AYTU) generated $3.3M in free cash flow during fiscal year 2026. This represents a 250.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AYTU BioPharma, Inc.'s operating cash flow?
AYTU BioPharma, Inc. (AYTU) generated $3.3M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are AYTU BioPharma, Inc.'s total assets?
AYTU BioPharma, Inc. (AYTU) had $105.0M in total assets as of fiscal year 2026, including both current and long-term assets.
What are AYTU BioPharma, Inc.'s capital expenditures?
AYTU BioPharma, Inc. (AYTU) invested $29K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is AYTU BioPharma, Inc.'s current ratio?
AYTU BioPharma, Inc. (AYTU) had a current ratio of 1.13 as of fiscal year 2026, which is considered adequate.
What is AYTU BioPharma, Inc.'s debt-to-equity ratio?
AYTU BioPharma, Inc. (AYTU) had a debt-to-equity ratio of 0.26 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is AYTU BioPharma, Inc.'s return on assets (ROA)?
AYTU BioPharma, Inc. (AYTU) had a return on assets of -13.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is AYTU BioPharma, Inc.'s P/E ratio?
AYTU BioPharma, Inc. (AYTU) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $22.0M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AYTU BioPharma, Inc.'s price-to-sales ratio?
AYTU BioPharma, Inc. (AYTU) trades at 0.4x sales, its market capitalization divided by revenue of $57.6M revenue, FY2026. The market capitalization is $22.0M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AYTU BioPharma, Inc.'s Altman Z-Score?
AYTU BioPharma, Inc. (AYTU) has an Altman Z-Score of -4.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is AYTU BioPharma, Inc.'s Piotroski F-Score?
AYTU BioPharma, Inc. (AYTU) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AYTU BioPharma, Inc.'s earnings high quality?
AYTU BioPharma, Inc. (AYTU) reported a net loss of $14.3M while generating $3.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can AYTU BioPharma, Inc. cover its interest payments?
AYTU BioPharma, Inc. (AYTU) reported an operating loss of $8.3M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is AYTU BioPharma, Inc.?
AYTU BioPharma, Inc. (AYTU) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.